FX06: An Investigational Drug Successfully Treated Ebola Patient
According to report presented in The Lancet explains how a male physician who developed Ebola in Sierra Leone survived the disease soon after being treated with a medicine that is being examined for use against vascular leakage syndrome.
The 38-year-old doctor was handling an Ebola therapy unit in Sierra Leone when he developed diarrhea and fever on September 28th of this year. The same day, it was verified he had developed Ebola.
He was traveled to Frankfurt University Medical center in Germany 5 days later, where he was kept in a specialised isolation unit and treated with an investigational drug known as FX06 – a fibrin extracted peptide that has been revealed to be efficient in decreasing vascular leakage in mice with Dengue hemorrhagic shock.
Dr. Timo Wolf and peers, of Frankfurt University Hospital, show how the man’s therapy with the investigational drug was a success, and they call for it to be evaluated in clinical studies for Ebola.
No Ebola virus discovered in blood 30 days after therapy with FX06
The individual revealed symptoms of vascular leakage and failure of the gastrointestinal tract, lungs, and kidneys among other body parts, within three days of being admitted to the medical center.
After putting the individual on kidney dialysis and a ventilator, Dr. Wolf and peers gave him antibiotics and a 3-day therapy course with FX06 in order to protect against additional vascular leakage.
In the beginning, the individual obtained 400 mg of FX06 intravenously – 200 mg were given via a slow bolus injection and after 10 mins, one more 200-mg dose was provided. The sufferer then obtained 200 mg of FX06 via an intravenous bolus injection every 12 hours thereafter for 3 days.
Right after the treatment, Dr. Wolf and co-workers say they noticed a considerable improvement in the sufferer’s respiratory and vascular functionality. This coincided with a decreased viral load in his blood. Following 30 days, no Ebola virus could be found. The physician has now made a full recovery.
Dependent on this case, the authors think FX06 should be analyzed additional for treatment of Ebola:
“We recommend FX06 as a possibly valuable treatment candidate for vascular leak syndrome in Ebola virus disease.
In view of the emergency for action in light of the present outbreak, where validated treatments are desperately required, the effectiveness of FX06 should soon be evaluated in clinical studies or at least by standardized collection of data from sufferers with Ebola virus disease who obtained it in a compassionate use setting.”